| BSX |
Boston Scientific Corporation |
72%
|
Reciprocal relationship from BSX graph: Reciprocal relationship from ICCM graph: ss potential disruptions that we may encounter. In the future, as we scale up our sales and production further, we may… |
| BSX |
Boston Scientific Corporation |
72%
|
ss potential disruptions that we may encounter. In the future, as we scale up our sales and production further, we may implement a turnkey operation with select manufacturers for our probes. We enter… |
| BEIJING-SUNSHINE-YIBANG-MEDICAL-TECHNOLOGY-CO-LT |
BEIJING-SUNSHINE-YIBANG-MEDICAL-TECHNOLOGY-CO-LT |
62%
|
overy plans to address potential disruptions that we may encounter. In the future, as we scale up our sales and production further, we may implement a turnkey operation with select manufacturers for … |
| BOSTON-SCIENTIFIC-CORPORATION-ENDOCARE-INC |
BOSTON-SCIENTIFIC-CORPORATION-ENDOCARE-INC |
62%
|
overy plans to address potential disruptions that we may encounter. In the future, as we scale up our sales and production further, we may implement a turnkey operation with select manufacturers for … |
| CONCEPT-GROUP-LLC |
CONCEPT-GROUP-LLC |
62%
|
LTD, J.H. Avidan LTD and Concept Group LLC. We consistently monitor our inventory levels, manufacturing and distribution capabilities, and maintain recovery plans to address potential disruptions tha… |
| EMT-ELECTRONICS-MANUFACTURING-TECHNOLOGIES-LTD |
EMT-ELECTRONICS-MANUFACTURING-TECHNOLOGIES-LTD |
62%
|
e ASBrS updated its treatment resource guide to include cryoablation as a recommended option for the treatment of low-risk breast cancer in patients aged 70 and above. We are also continually seeking… |
| GALIL-MEDICAL-LTD |
GALIL-MEDICAL-LTD |
62%
|
overy plans to address potential disruptions that we may encounter. In the future, as we scale up our sales and production further, we may implement a turnkey operation with select manufacturers for … |
| HYGEA-MEDICAL-TECHNOLOGY-CO-LTD |
HYGEA-MEDICAL-TECHNOLOGY-CO-LTD |
62%
|
d litigation, reputational harm, and other consequences. We have direct or indirect interactions with officials and employees of government agencies or government-affiliated hospitals, universities a… |
| ICECURE-MEDICAL-HK-LIMITED |
ICECURE-MEDICAL-HK-LIMITED |
62%
|
al knowledge of the statute or specific intent to violate it. ● The Federal False Claims Act imposes civil penalties, including through civil whistleblower or qui tam actions, against individuals or … |
| ICECURE-MEDICAL-INC |
ICECURE-MEDICAL-INC |
62%
|
s. We have based these forward-looking statements on assumptions and assessments made by our management in light of their experience and their perception of historical trends, current conditions, exp… |
| INDIA-NOVOMED-LTD |
INDIA-NOVOMED-LTD |
62%
|
e ASBrS updated its treatment resource guide to include cryoablation as a recommended option for the treatment of low-risk breast cancer in patients aged 70 and above. We are also continually seeking… |
| JAPAN-IF-TERUMO-CORPORATION |
JAPAN-IF-TERUMO-CORPORATION |
62%
|
ecreases our manufacturers' ability to negotiate pricing with their suppliers. Any shortage or obsolescence of raw materials, components or accessories, or our inability to control costs associated t… |
| KENNETH-TOMKOVICH-MD-CO |
KENNETH-TOMKOVICH-MD-CO |
62%
|
e ASBrS updated its treatment resource guide to include cryoablation as a recommended option for the treatment of low-risk breast cancer in patients aged 70 and above. We are also continually seeking… |
| NEUWAVE-MEDICAL-INC |
NEUWAVE-MEDICAL-INC |
62%
|
d litigation, reputational harm, and other consequences. We have direct or indirect interactions with officials and employees of government agencies or government-affiliated hospitals, universities a… |
| SANARUS-MEDICAL-INC |
SANARUS-MEDICAL-INC |
62%
|
overy plans to address potential disruptions that we may encounter. In the future, as we scale up our sales and production further, we may implement a turnkey operation with select manufacturers for … |
| SHANGHAI-MEDTECH-CO-LTD |
SHANGHAI-MEDTECH-CO-LTD |
62%
|
al knowledge of the statute or specific intent to violate it. ● The Federal False Claims Act imposes civil penalties, including through civil whistleblower or qui tam actions, against individuals or … |
| SIEMENS-HEALTHINEERS-AG-HYGEA-MEDICAL-TECHNOLOGY |
SIEMENS-HEALTHINEERS-AG-HYGEA-MEDICAL-TECHNOLOGY |
62%
|
overy plans to address potential disruptions that we may encounter. In the future, as we scale up our sales and production further, we may implement a turnkey operation with select manufacturers for … |
| TERUMO-CORPORATION-IF-TERUMO-CORPORATION |
TERUMO-CORPORATION-IF-TERUMO-CORPORATION |
62%
|
ecreases our manufacturers' ability to negotiate pricing with their suppliers. Any shortage or obsolescence of raw materials, components or accessories, or our inability to control costs associated t… |
